NATIONAL HARBOR, MARYLAND — Cilcare, a French-US biopharmaceutical company specializing in auditory science, announced a series of U.S. investments at the SelectUSA Investment Summit 2026, including plans for a clinical trial of its lead tinnitus drug candidate at Massachusetts General Hospital, expanded preclinical capacity through its partner CBSET, and the launch of a U.S....
✦ Clinical Takeaway ✦
No actionable clinical change at this time; the tinnitus trial is only planned and no results are available yet.
✦ Why It Matters ✦
A planned clinical trial for a novel tinnitus drug candidate at a major academic center signals growing pharmaceutical investment in tinnitus treatment, an area with no currently approved pharmacological therapy.
✦ Key Points ✦
- 01Cilcare is expanding U.S. operations via a partnership with CBSET, a contract research organization.
- 02